β-Score

An assessment of β-cell function after islet transplantation

  1. Edmond A. Ryan, MD1,
  2. Breay W. Paty, MD1,
  3. Peter A. Senior, MD, PHD1,
  4. Jonathan R.T. Lakey, PHD2,
  5. David Bigam, MD2 and
  6. A.M. James Shapiro, MD, PHD2
  1. 1Department of Medicine, Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, Edmonton, Alberta, Canada
  2. 2Department of Surgery, Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, Edmonton, Alberta, Canada
  1. Address correspondence and reprint requests to Edmond A. Ryan, 362 Heritage Medical Research Centre, Edmonton, Alberta, Canada T6G 2S2. E-mail: edmond.ryan{at}ualberta.ca

Abstract

OBJECTIVE—Success after islet transplantation can be defined in terms of insulin independence, C-peptide secretion, or glycemic control. These measures are interdependent and all need to be considered in evaluating β-cell function after islet transplantation. For the current study, a composite β-score was developed that provides an integrated measure of β-cell function success after islet transplantation.

RESEARCH DESIGN AND METHODS—The proposed scoring system gave 2 points each for normal fasting glucose, HbA1c, stimulated C-peptide, and absence of insulin or oral hypoglycemic agent use. No points were awarded if the fasting glucose was in the diabetic range, the HbA1c was >6.9%, C-peptide secretion was absent on stimulation, or daily insulin use was in excess of 0.24 units/kg. One point was given for intermediate values. The score ranged from 0 to 8 and was correlated with the glucose value 90 min after a standard mixed meal challenge (n = 218) in 57 subjects before and after islet transplantation. The score was also used to follow subjects for up to 5 years after islet transplantation.

RESULTS—The β-score correlated well with the plasma glucose level 90 min after a mixed meal challenge (r = −0.849, P < 0.001). On follow-up, the β-score rose after the first transplant and was maintained up to 5 years, demonstrating continuing function of the transplanted β-cells.

CONCLUSIONS—The β-score provides a simple clinical scoring system that encompasses glycemic control, diabetes therapy, and endogenous insulin secretion that correlates well with physiological measures of β-cell function. On this basis, it is suitable as an overall measure of β-cell transplant function. The β-score gives an integrated measure of β-cell function as a continuum that may be more useful than simply assessing the presence or absence of insulin independence.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted November 11, 2004.
    • Received August 11, 2004.
« Previous | Next Article »Table of Contents